Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study

BACKGROUND: Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. Pitavastatin has less drug-drug interactions and demonstrable efficacy in decreasing lipid levels in non HIV-infected indivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wongprikorn, Asita, Sukasem, Chonlaphat, Puangpetch, Apichaya, Numthavej, Pawin, Thakkinstian, Ammarin, Kiertiburanakul, Sasisopin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909195/
https://www.ncbi.nlm.nih.gov/pubmed/27304841
http://dx.doi.org/10.1371/journal.pone.0157531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909195/
https://www.ncbi.nlm.nih.gov/pubmed/27304841
http://dx.doi.org/10.1371/journal.pone.0157531

Ejemplares similares